Care Patterns, Outcomes, and Costs in Peripheral T-Cell Lymphoma Patients with First-Line Treatment in Routine Clinical Practice in Europe

Purpose Limited real-world data exist on care patterns in peripheral T-cell lymphoma (PTCL) patients. We report care patterns and outcomes among PTCL patients in France, the United Kingdom (UK), Germany, and Italy in the first-line setting. Patients and Methods A retrospective chart review was undertaken for adults with newly diagnosed PTCL. Eligible patients received ≥1 line of therapy (LOT) and had clinical data for ≥1 year after diagnosis or until death. Outcomes included treatments, best response at the end of 1LOT, progression-free survival (PFS) and overall survival (OS). Results Data from 195 patients (France=53; UK=56; Germany=56; Italy=30) were collected. Median age at diagnosis was 62.0 years, with 73.3% at stage III/IV. The most common histological subtype was PTCL–not otherwise specified (36.9%). For 1LOT, 49.7% and 36.4% of patients received CHOP and CHOEP regimens, respectively. A complete response was reported in 59.7% of patients. Median PFS from 1LOT initiation was 49.4 months; median OS was 77.1 months. First-line treatment costs were highest in the UK. The cost drivers were adjunctive therapy in France and Germany; stem cell transplant and hospitalization in the UK and Italy, respectively. Conclusion This analysis improves the understanding of treatment outcomes and costs in PTCL patients in Europe.